- Home
- NRIX vs MCRI Comparison
NRIX vs MCRI Comparison
Compare NRIX & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- MCRI
- Stock Information
- Founded
- NRIX 2009
- MCRI 1972
- Country
- NRIX United States
- MCRI United States
- Employees
- NRIX N/A
- MCRI N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- MCRI Hotels/Resorts
- Sector
- NRIX Health Care
- MCRI Consumer Discretionary
- Exchange
- NRIX Nasdaq
- MCRI Nasdaq
- Market Cap
- NRIX 1.4B
- MCRI 1.6B
- IPO Year
- NRIX 2020
- MCRI 1993
- Fundamental
- Price
- NRIX $16.87
- MCRI $89.40
- Analyst Decision
- NRIX Strong Buy
- MCRI Hold
- Analyst Count
- NRIX 16
- MCRI 5
- Target Price
- NRIX $31.75
- MCRI $84.00
- AVG Volume (30 Days)
- NRIX 658.9K
- MCRI 109.9K
- Earning Date
- NRIX 04-09-2025
- MCRI 02-11-2025
- Dividend Yield
- NRIX N/A
- MCRI 1.34%
- EPS Growth
- NRIX N/A
- MCRI 18.10
- EPS
- NRIX N/A
- MCRI 4.96
- Revenue
- NRIX $54,549,000.00
- MCRI $522,186,000.00
- Revenue This Year
- NRIX $3.28
- MCRI $2.73
- Revenue Next Year
- NRIX $6.73
- MCRI $2.07
- P/E Ratio
- NRIX N/A
- MCRI $18.02
- Revenue Growth
- NRIX N/A
- MCRI 4.13
- 52 Week Low
- NRIX $10.17
- MCRI $64.50
- 52 Week High
- NRIX $29.56
- MCRI $96.11
- Technical
- Relative Strength Index (RSI)
- NRIX 35.92
- MCRI 56.09
- Support Level
- NRIX $16.56
- MCRI $90.43
- Resistance Level
- NRIX $18.07
- MCRI $96.11
- Average True Range (ATR)
- NRIX 0.91
- MCRI 2.59
- MACD
- NRIX -0.13
- MCRI 0.22
- Stochastic Oscillator
- NRIX 9.95
- MCRI 52.28
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.